主页 > 医学动态 >
【Cancer cell】促红细胞生成素和粒细胞集落刺激因
Purpose: To assess the effect of erythropoietin (EPO) plus granulocyte-colony stimulating factor (G-CSF) treatment on survival and leukemic transformation in myelodysplastic syndrome (MDS).
Patients and Methods: We compared the long-term outcome of patients with MDS treated with EPO plus G-CSF (n = 121) with untreated patients (n = 237) with MDS using multivariate Cox regression with delayed entry, for the first time adjusting for all major prognostic variables (WHO classification, karyotype, cytopenias, level of transfusion-need, age, and sex).
Results: The erythroid response rate to EPO plus G-CSF was 39%, and the median response duration 23 months (range, 3 to 116+). In the multivariate analysis, treatment was associated with improved overall survival (hazard ratio, 0.61; 95% CI, 0.44 to 0.83; P = .002). Interestingly, this positive association was primarily observed in patients requiring fewer than 2 units of RBCs per month. Treatment was not linked to the rate of acute myeloid leukemia in any defined subgroup, including patients with an increase of marrow blasts or an unfavorable karyotype.
Conclusion: The inherent risk of leukemic evolution in MDS makes the current investigation highly relevant, in light of the recent reports of potential negative effects of EPO treatment on outcome in patients with cancer. We conclude that treatment of anemia in MDS with EPO plus G-CSF may have a positive impact on outcome in patients with no or low transfusion need, while not affecting the risk of leukemic transformation.
published online ahead of print at www.jco.org on June 16, 2008.
http://jco.ascopubs.org/cgi/content/abstract/26/21/3607 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。
促红细胞生成素和粒细胞集落刺激因子治疗与提高骨髓增生异常综合征患者生存率有关
Purpose: To assess the effect of erythropoietin (EPO) plus granulocyte-colony stimulating factor (G-CSF) treatment on survival and leukemic transformation in myelodysplastic syndrome (MDS).
目的：评价促红细胞生成素（EPO）与粒细胞集落刺激因子（G-CSF）共同治疗对骨髓增生异常综合征（MDS）生存率和白血病转化的影响。
Patients and Methods: We compared the long-term outcome of patients with MDS treated with EPO plus G-CSF (n = 121) with untreated patients (n = 237) with MDS using multivariate Cox regression with delayed entry, for the first time adjusting for [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-08-28 17:17
医学,生命科学网